Advertisement

Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

  • Etsuko HashimotoEmail author
  • Masaki Iwai
  • Arief A. Suriawinata
Chapter

Abstract

Alcoholic liver disease (ALD) has been reported worldwide with a prevalence of 0–20% and remains one of the major causes of liver disease. The spectrum of ALD includes fatty liver, alcoholic hepatitis, alcoholic fibrosis, and cirrhosis. Hepatocellular carcinoma may also develop, especially in patients with cirrhosis. Histologically, ALD shows simple steatosis and steatohepatitis and eventually progresses to cirrhosis. These clinical and histological features overlap.

Keywords

Alcoholic liver disease Nonalcoholic fatty liver disease Nonalcoholic fatty liver Nonalcoholic steatohepatitis Fatty liver Cirrhosis Hepatocellular carcinoma 

Notes

Acknowledgments

Prof. Paul Y. Kwo is acknowledged for his contribution in editing this chapter.

References

  1. 1.
    O’Shea RS, Dasarathy S, McCullough AJ, et al. AASLD practice Guildelines; alcoholic liver disease. Hepatology. 2010;51:307–28.CrossRefGoogle Scholar
  2. 2.
    Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113:175–94.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399–420.CrossRefGoogle Scholar
  4. 4.
    Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructural and histologic progression. Gastroenterology. 1982;83:777–85.PubMedGoogle Scholar
  5. 5.
    Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease. A study of 200 cases. Gastroenterology. 1982;83:786–96.PubMedGoogle Scholar
  6. 6.
    Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (part 1 of a literature survey). Hepatology. 1994;20:1061–77.CrossRefGoogle Scholar
  7. 7.
    Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.CrossRefGoogle Scholar
  8. 8.
    Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of Patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.CrossRefGoogle Scholar
  9. 9.
    Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364–77.CrossRefGoogle Scholar
  10. 10.
    easloffice@easloffice.eu EAftSotLEEa, (EASD) EAftSoD, (EASO) EAftSoO. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.Google Scholar
  11. 11.
    Wong VW, Chan WK, Hashimoto E, et al. The Asia-Pacific working party on nonalcoholic fatty liver disease guidelines 2017 part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.CrossRefGoogle Scholar
  12. 12.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and Management of Nonalcoholic Fatty Liver Disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017;67:328.  https://doi.org/10.1002/hep.29367.CrossRefPubMedGoogle Scholar
  13. 13.
    McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–55.CrossRefGoogle Scholar
  14. 14.
    Dufour JF. Time to abandon NASH? Hepatology. 2016;63:9–10.CrossRefGoogle Scholar
  15. 15.
    Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic proc. 1980;55:434–8.Google Scholar
  16. 16.
    Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges. Hepatol Res. 2014:1–9.Google Scholar
  17. 17.
    Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefGoogle Scholar
  18. 18.
    Brunt EM, Janney CG, DiBisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefGoogle Scholar
  19. 19.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefGoogle Scholar
  20. 20.
    Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.CrossRefGoogle Scholar
  21. 21.
    Bedossa P. FLIP pathology consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–75.CrossRefGoogle Scholar
  22. 22.
    Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97.CrossRefGoogle Scholar
  23. 23.
    Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–54.CrossRefGoogle Scholar
  24. 24.
    Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–8.CrossRefGoogle Scholar
  25. 25.
    Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res. 2012;42:1–14.CrossRefGoogle Scholar
  26. 26.
    Hannah WN, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2016;64:2234–43.CrossRefGoogle Scholar
  27. 27.
    Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol. 2004;39(12):1215–8.CrossRefGoogle Scholar
  28. 28.
    Suzuki D, Hashimoto E, Kaneda H, et al. Liver failure caused by non-alcoholic steatohepatitis in an obese young male. J Gastroenterol Hepatol. 2005;20:327–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Etsuko Hashimoto
    • 1
    Email author
  • Masaki Iwai
    • 2
  • Arief A. Suriawinata
    • 3
  1. 1.TokyoJapan
  2. 2.KyotoJapan
  3. 3.New HampshireUSA

Personalised recommendations